Portfolio Holdings Detail for ISIN IE00BYXG2H39
| Stock Name / Fund | iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | BTEC(USD) LSE |
| ETF Ticker | BTEK(GBP) LSE |
| ETF Ticker | 2B70(EUR) F |
| ETF Ticker | 2B70.DE(EUR) CXE |
| ETF Ticker | BTEC.LS(USD) CXE |
| ETF Ticker | BTEK.LS(GBP) CXE |
| ETF Ticker | BTEC.L(GBP) LSE |
| ETF Ticker | BTEK.L(GBP) LSE |
Holdings detail for ENTA
| Stock Name | Enanta Pharmaceuticals Inc |
| Ticker | ENTA(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US29251M1062 |
| LEI | 529900SSN4DODDQSN594 |
Show aggregate ENTA holdings
News associated with ENTA
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $20.20 Average PT from Brokerages
- Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) have earned a consensus rating of “Buy” from the five analysts that are presently covering the company, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a buy rating. The average 12 month target price among brokerages that have updated their coverage […] - 2025-09-18 02:12:52
- Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Lowered to $12.00 at Evercore ISI
- Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) had its price target cut by research analysts at Evercore ISI from $20.00 to $12.00 in a research note issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Evercore ISI’s target price points to a potential upside of 61.07% from the […] - 2025-09-17 02:46:43
- Enanta Pharmaceuticals (NASDAQ:ENTA) Coverage Initiated by Analysts at Westpark Capital
- Equities researchers at Westpark Capital assumed coverage on shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) in a report released on Tuesday,Benzinga reports. The firm set a “buy” rating and a $24.00 price target on the biotechnology company’s stock. Westpark Capital’s price objective indicates a potential upside of 172.11% from the stock’s current price. […] - 2025-09-04 04:34:54
- XTX Topco Ltd Invests $110,000 in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
- XTX Topco Ltd purchased a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 19,941 shares of the biotechnology company’s stock, valued at approximately $110,000. Other large investors also recently modified their […] - 2025-08-15 05:02:52
- Cwm LLC Increases Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
- Cwm LLC raised its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 763.7% during the first quarter, HoldingsChannel reports. The firm owned 17,585 shares of the biotechnology company’s stock after purchasing an additional 15,549 shares during the period. Cwm LLC’s holdings in Enanta Pharmaceuticals were worth $97,000 at the end of the most […] - 2025-07-31 04:38:52
- Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) PT at $18.00
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has been given an average rating of “Moderate Buy” by the five analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the […] - 2025-07-01 02:51:01
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
- UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 6.4% during the fourth quarter, Holdings Channel reports. The fund owned 159,729 shares of the biotechnology company’s stock after selling 10,886 shares during the quarter. UBS AM a distinct business unit […] - 2025-06-11 05:46:51
- Two Sigma Investments LP Reduces Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
- Two Sigma Investments LP reduced its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 66.4% during the 4th quarter, Holdings Channel reports. The fund owned 64,283 shares of the biotechnology company’s stock after selling 126,974 shares during the period. Two Sigma Investments LP’s holdings in Enanta Pharmaceuticals were worth $370,000 as of its […] - 2025-06-11 04:28:55
- Ameriprise Financial Inc. Has $405,000 Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
- Ameriprise Financial Inc. decreased its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 78.5% during the 4th quarter, HoldingsChannel reports. The fund owned 70,427 shares of the biotechnology company’s stock after selling 257,884 shares during the period. Ameriprise Financial Inc.’s holdings in Enanta Pharmaceuticals were worth $405,000 at the end of […] - 2025-06-05 04:22:54
- Two Sigma Advisers LP Trims Stock Holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
- Two Sigma Advisers LP reduced its stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 32.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 156,300 shares of the biotechnology company’s stock after selling 76,700 shares during the quarter. Two Sigma […] - 2025-06-02 05:13:00
- Millennium Management LLC Buys 165,692 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
- Millennium Management LLC boosted its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 22.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 896,987 shares of the biotechnology company’s stock after buying an additional 165,692 shares during the period. Millennium Management LLC’s holdings in Enanta Pharmaceuticals were worth $5,158,000 at the […] - 2025-05-29 04:52:58
- BNP Paribas Financial Markets Buys 35,695 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
- BNP Paribas Financial Markets raised its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 100.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 71,104 shares of the biotechnology company’s stock after buying an additional 35,695 shares during the period. BNP Paribas […] - 2025-05-26 05:02:49
- Cubist Systematic Strategies LLC Sells 2,665 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
- Cubist Systematic Strategies LLC trimmed its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 11.6% in the fourth quarter, HoldingsChannel reports. The firm owned 20,255 shares of the biotechnology company’s stock after selling 2,665 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Enanta Pharmaceuticals were worth $116,000 as of […] - 2025-05-19 05:01:00
- Wells Fargo & Company MN Has $91,000 Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
- Wells Fargo & Company MN grew its holdings in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 69.6% during the fourth quarter, Holdings Channel.com reports. The firm owned 15,881 shares of the biotechnology company’s stock after acquiring an additional 6,518 shares during the period. Wells Fargo & Company MN’s holdings in Enanta Pharmaceuticals were worth […] - 2025-05-13 04:17:01
- Invesco Ltd. Boosts Stake in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)
- Invesco Ltd. increased its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 7.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,614 shares of the biotechnology company’s stock after acquiring an additional 3,186 shares during the quarter. Invesco Ltd.’s holdings […] - 2025-05-05 04:26:47
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Sold by Renaissance Technologies LLC
- Renaissance Technologies LLC lowered its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 5.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 498,000 shares of the biotechnology company’s stock after selling 26,900 shares during the quarter. Renaissance Technologies LLC’s […] - 2025-04-25 05:17:02
- Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Crosses Below 200-Day Moving Average – Here’s Why
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report)’s share price crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $8.32 and traded as low as $5.84. Enanta Pharmaceuticals shares last traded at $5.88, with a volume of 166,938 shares traded. Analyst […] - 2025-03-26 05:00:48
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Purchased by AlphaQuest LLC
- AlphaQuest LLC boosted its position in Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) by 16.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 22,260 shares of the biotechnology company’s stock after purchasing an additional 3,137 shares during the quarter. AlphaQuest LLC owned about 0.10% […] - 2025-03-18 06:38:51
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Rating of “Moderate Buy” from Brokerages
- Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) have received an average rating of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has given a strong buy […] - 2025-03-11 04:30:57
- Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $17.25
- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating on the […] - 2025-02-17 05:01:09
- Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to “Sell” at StockNews.com
- StockNews.com lowered shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) from a hold rating to a sell rating in a research note published on Tuesday morning. Several other research analysts have also weighed in on the stock. Robert W. Baird lowered their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set […] - 2025-02-12 06:24:52
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) ENTA holdings
| Date | Number of ENTA Shares Held | Base Market Value of ENTA Shares | Local Market Value of ENTA Shares | Change in ENTA Shares Held | Change in ENTA Base Value | Current Price per ENTA Share Held | Previous Price per ENTA Share Held |
|---|
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of ENTA by Blackrock for IE00BYXG2H39
Show aggregate share trades of ENTA| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-10-06 | BUY | 102 | 11.350 | 11.590 | 11.566 | USD 1,180 | 6.78 |
| 2025-10-03 | BUY | 238 | 10.330 | 10.786 | 10.740 | USD 2,556 | 6.76 |
| 2025-10-02 | BUY | 34 | 10.330 | 10.950 | 10.888 | USD 370 | 6.74 |
| 2025-10-01 | BUY | 68 | 10.610 | 11.850 | 11.726 | USD 797 | 6.72 |
| 2025-09-26 | BUY | 68 | 7.900 | 8.020 | 8.008 | USD 545 | 6.64 |
| 2025-09-25 | BUY | 68 | 7.750 | 7.970 | 7.948 | USD 540 | 6.63 |
| 2025-09-18 | BUY | 34 | 7.840 | 7.920 | 7.912 | USD 269 | 6.62 |
| 2025-09-17 | BUY | 102 | 7.540 | 7.822 | 7.794 | USD 795 | 6.61 |
| 2025-09-11 | SELL | -34 | 8.660 | 8.790 | 8.777 | USD -298 | 6.58  Loss of -75 on sale |
| 2025-09-10 | BUY | 68 | 8.330 | 9.090 | 9.014 | USD 613 | 6.57 |
| 2025-09-05 | SELL | -34 | 8.850 | 9.080 | 9.057 | USD -308 | 6.53 Loss of -86 on sale |
| 2025-08-29 | SELL | -102 | 8.400 | 8.825 | 8.782 | USD -896 | 6.47 Loss of -235 on sale |
| 2025-08-27 | BUY | 68 | 8.530 | 8.750 | 8.728 | USD 594 | 6.45 |
| 2025-08-26 | SELL | -34 | 8.650 | 8.760 | 8.749 | USD -297 | 6.43 Loss of -79 on sale |
| 2025-08-25 | BUY | 34 | 8.660 | 8.875 | 8.853 | USD 301 | 6.42 |
| 2025-08-20 | SELL | -136 | 8.820 | 8.840 | 8.838 | USD -1,202 | 6.39 Loss of -333 on sale |
| 2025-08-18 | BUY | 68 | 8.170 | 8.315 | 8.300 | USD 564 | 6.37 |
| 2025-08-08 | SELL | -68 | 6.900 | 7.060 | 7.044 | USD -479 | 6.34 Loss of -48 on sale |
| 2025-08-05 | BUY | 34 | 7.410 | 7.450 | 7.446 | USD 253 | 6.33 |
| 2025-08-01 | SELL | -102 | 7.110 | 7.650 | 7.596 | USD -775 | 6.32 Loss of -131 on sale |
| 2025-07-30 | BUY | 136 | 7.610 | 8.310 | 8.240 | USD 1,121 | 6.30 |
| 2025-07-17 | SELL | -68 | 7.230 | 7.420 | 7.401 | USD -503 | 6.21 Loss of -81 on sale |
| 2025-07-11 | SELL | -272 | 6.560 | 7.040 | 6.992 | USD -1,902 | 6.19 Loss of -218 on sale |
| 2025-07-07 | BUY | 102 | 7.650 | 8.000 | 7.965 | USD 812 | 6.15 |
| 2025-07-02 | BUY | 1,870 | 7.970 | 8.228 | 8.202 | USD 15,338 | 6.11 |
| 2025-06-25 | BUY | 68 | 7.450 | 7.470 | 7.468 | USD 508 | 6.06 |
| 2025-06-11 | BUY | 68 | 7.950 | 8.470 | 8.418 | USD 572 | 5.95 |
| 2025-06-10 | BUY | 68 | 7.580 | 7.700 | 7.688 | USD 523 | 5.93 |
| 2025-06-04 | SELL | -34 | 7.110 | 7.405 | 7.376 | USD -251 | 5.88 Loss of -51 on sale |
| 2025-04-23 | BUY | 34 | 5.600 | 5.750 | 5.735 | USD 195 | 5.94 |
| 2025-04-10 | SELL | -272 | 4.260 | 4.450 | 4.431 | USD -1,205 | 6.07  Profit of 446 on sale |
| 2025-04-08 | SELL | -34 | 4.460 | 4.900 | 4.856 | USD -165 | 6.12 Profit of 43 on sale |
| 2025-04-07 | SELL | -34 | 4.640 | 4.780 | 4.766 | USD -162 | 6.14 Profit of 47 on sale |
| 2025-04-04 | SELL | -170 | 4.730 | 5.010 | 4.982 | USD -847 | 6.17 Profit of 201 on sale |
| 2025-04-01 | BUY | 136 | 5.320 | 5.585 | 5.559 | USD 756 | 6.19 |
| 2025-03-31 | SELL | -102 | 5.520 | 5.650 | 5.637 | USD -575 | 6.21 Profit of 58 on sale |
| 2025-03-14 | SELL | -544 | 6.650 | 7.030 | 6.992 | USD -3,804 | 6.22 Loss of -422 on sale |
| 2025-03-07 | SELL | -68 | 7.220 | 7.300 | 7.292 | USD -496 | 6.12 Loss of -80 on sale |
| 2025-03-04 | SELL | -34 | 7.240 | 7.350 | 7.339 | USD -250 | 6.04 Loss of -44 on sale |
| 2025-02-25 | BUY | 68 | 8.490 | 8.585 | 8.576 | USD 583 | 5.77 |
| 2025-02-19 | SELL | -34 | 8.300 | 8.550 | 8.525 | USD -290 | 5.45 Loss of -105 on sale |
| 2025-02-13 | BUY | 102 | 7.500 | 7.928 | 7.885 | USD 804 | 5.17 |
| 2025-02-12 | BUY | 34 | 5.860 | 5.930 | 5.923 | USD 201 | 5.14 |
| 2025-02-11 | BUY | 136 | 5.590 | 5.988 | 5.948 | USD 809 | 5.13 |
| 2025-01-17 | BUY | 136 | 5.250 | 5.310 | 5.304 | USD 721 | 5.07 |
| 2025-01-16 | BUY | 136 | 4.850 | 5.060 | 5.039 | USD 685 | 5.10 |
| 2025-01-10 | SELL | -68 | 5.090 | 5.185 | 5.175 | USD -352 | 5.30 Profit of 9 on sale |
| 2025-01-08 | SELL | -136 | 5.160 | 5.390 | 5.367 | USD -730 | 5.59 Profit of 30 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of ENTA
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 12,295 | 239 | 41,934 | 29.3% |
| 2025-09-18 | 19,985 | 1,444 | 138,983 | 14.4% |
| 2025-09-17 | 24,070 | 0 | 99,733 | 24.1% |
| 2025-09-16 | 18,892 | 4,327 | 91,034 | 20.8% |
| 2025-09-15 | 39,488 | 54 | 188,961 | 20.9% |
| 2025-09-12 | 15,936 | 0 | 124,503 | 12.8% |
| 2025-09-11 | 16,783 | 0 | 107,826 | 15.6% |
| 2025-09-10 | 12,675 | 0 | 113,390 | 11.2% |
| 2025-09-09 | 10,922 | 0 | 28,358 | 38.5% |
| 2025-09-08 | 16,302 | 0 | 47,216 | 34.5% |
| 2025-09-05 | 8,154 | 0 | 44,372 | 18.4% |
| 2025-09-04 | 12,969 | 0 | 53,476 | 24.3% |
| 2025-09-03 | 22,228 | 0 | 117,098 | 19.0% |
| 2025-09-02 | 28,577 | 122 | 225,546 | 12.7% |
| 2025-08-29 | 8,307 | 0 | 22,033 | 37.7% |
| 2025-08-28 | 5,831 | 0 | 25,231 | 23.1% |
| 2025-08-27 | 7,561 | 137 | 17,609 | 42.9% |
| 2025-08-26 | 6,438 | 0 | 22,601 | 28.5% |
| 2025-08-25 | 8,765 | 0 | 28,059 | 31.2% |
| 2025-08-22 | 9,526 | 0 | 30,472 | 31.3% |
| 2025-08-21 | 14,365 | 0 | 52,800 | 27.2% |
| 2025-08-20 | 34,432 | 0 | 153,592 | 22.4% |
| 2025-08-19 | 37,885 | 0 | 167,744 | 22.6% |
| 2025-08-18 | 21,364 | 167 | 49,987 | 42.7% |
| 2025-08-15 | 10,471 | 0 | 54,572 | 19.2% |
| 2025-08-14 | 15,255 | 0 | 61,627 | 24.8% |
| 2025-08-13 | 44,682 | 0 | 100,744 | 44.4% |
| 2025-08-12 | 26,371 | 0 | 64,780 | 40.7% |
| 2025-08-11 | 16,943 | 0 | 56,694 | 29.9% |
| 2025-08-08 | 11,611 | 0 | 29,183 | 39.8% |
| 2025-08-07 | 14,608 | 0 | 35,966 | 40.6% |
| 2025-08-06 | 20,476 | 0 | 38,286 | 53.5% |
| 2025-08-05 | 26,450 | 0 | 47,296 | 55.9% |
| 2025-08-04 | 23,447 | 0 | 43,973 | 53.3% |
| 2025-08-01 | 44,240 | 0 | 85,883 | 51.5% |
| 2025-07-31 | 19,659 | 0 | 66,584 | 29.5% |
| 2025-07-30 | 45,501 | 0 | 90,706 | 50.2% |
| 2025-07-29 | 28,212 | 0 | 50,483 | 55.9% |
| 2025-07-28 | 52,036 | 0 | 150,243 | 34.6% |
| 2025-07-25 | 11,301 | 194 | 24,075 | 46.9% |
| 2025-07-24 | 9,730 | 0 | 31,343 | 31.0% |
| 2025-07-23 | 75,666 | 0 | 91,172 | 83.0% |
| 2025-07-22 | 14,552 | 0 | 191,308 | 7.6% |
| 2025-07-21 | 69,100 | 0 | 134,293 | 51.5% |
| 2025-07-18 | 46,535 | 0 | 83,297 | 55.9% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy